The first prenatal diagnoses of cystic fibrosis (CF) used the microvillar enzyme test of Brock et al. l This test can be applied to any pregnancy by amniocentesis at about 18 weeks of gestation, but its specificity is low unless the prior risk is 1 in 4 or greater. The discovery of DNA polymorphisms linked to the CF locus24 allowed prenatal diagnosis to be done earlier in pregnancy using chorion villus biopsy, with a lower error rate. We have described the principle of using these DNA markers elsewhere5 and summarised our experience with our first 30 cases. 6 The main limitation of this test is that it is applicable only to a minority of families, that is, those who have a surviving affected child.
DNA amplification using the polymerase chain reaction (PCR) Table 3 shows the distribution of marker alleles and table 4 the distribution of haplotypes among normal (NCF) and CF chromosomes. These results are generally similar to data on XV2c-KM19-CS-7 haplotypes reported12 from the UK, Denmark, Spain, and Finland, and to XV2c-KM19 haplotypes from Holland15 and Germany. 16 The distribution of haplotypes among both normal and CF chromosomes was not significantly different in our results and in the UK series of Estivill et (1-0-077)x0-878 0-077x (1-0 878)=86: 1.
Since the fetus inherited the B haplotype, it has a 1 in 87 chance of inheriting the CF gene from the mother, and an overall risk of 1 in 174 of being affected. In this family we were able to confirm the low risk using pJ3. 11, one of the less closely linked markers. 10 All five family members were heterozygous 2-1. In isolation this result means that the two surviving unaffected boys must share either two or no haplotypes. Since one boy is 2-1 and the other 2-2 with KM19 (fig 3) , they cannot share two haplotypes, so they must share none. Given that neither boy is both parents is at about 1/7 risk, and perhaps the microvillar enzyme test would be appropriate later in the pregnancy. All the results given here depend on being able to count the numbers of CF and non-CF chromosomes with each haplotype; hence, indeterminate haplotypes cause problems. These arise when the parents and the affected child are all heterozygous for two or more markers so that it is not possible to identify the CF and non-CF haplotypes. Sometimes analysis of grandparents or unaffected sibs will help, but some indeterminate cases will remain. As has been pointed out,16 the missing haplotypes are. not a random selection of those in the population, and ignoring them could bias the estimates of haplotype frequencies. Only a minority of haplotypes are indeterminate (16/155 in our data), so any bias will not be serious for common haplotypes, but the frequency of some rare haplotypes might be underestimated. We used the Hapmax program16 (kindly made available by Dr M Krawczak) to make a maximum likelihood estimate of the true haplotype frequencies from our data in table 4. The only significant change was an increase in the frequency of haplotype E on CF chromosomes from 2-8% (2/72, table 4) to 6-9%. The risks used throughout this paper are derived from combined data, ours plus those of Estivill et al,12 and in these combined data the E frequency is 7/130=5-4%. We conclude that indeterminate haplotypes are not seriously biasing our risk estimates.
